Study Evaluating Hemay022 in Combination With Endocrine Therapy In Subjects With ER Positive and HER2 Positive Advanced Breast Cancer
Phase 1
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2017-10-12
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 55
- Registration Number
- NCT03308201
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, China
Study Evaluating Hemay022 In Subjects With HER2-Positive Advanced Breast Cancer
- First Posted Date
- 2015-06-19
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 28
- Registration Number
- NCT02476539
- Locations
- 🇨🇳
Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China
Study Evaluating Hemay020 In Subjects With Advanced Solid Cancer
- First Posted Date
- 2015-06-10
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Tianjin Hemay Pharmaceutical Co., Ltd
- Target Recruit Count
- 10
- Registration Number
- NCT02467569
- Locations
- 🇨🇳
Sun Yat-Sen University Cancer Centre, Guangzhou, Guangdong, China
© Copyright 2025. All Rights Reserved by MedPath